Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Dupixent (dupilumab)
pCPA File Number:
22270
Negotiation Status:
Concluded with an LOI
Indication(s):
Asthma
Sponsor/Manufacturer:
sanofi-aventis Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2023-03-10
Negotiation Process Concluded:
2023-03-10